amiodarone has been researched along with Hypertension in 53 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report our experience using single high dose oral amiodarone for the cardioversion of recent onset atrial fibrillation to sinus rhythm in patient presenting with symptoms within 48 h." | 9.16 | Single high oral dose amiodarone for cardioversion of recent onset atrial fibrillation. ( Nadarasa, K; Williams, MJ, 2012) |
| "Sixty-two patients with recent-onset (less than or equal to 1 week) atrial fibrillation (New York Heart Association functional class 1 and 2) were randomized in a single-blind study to 1 of the following treatment groups: (1) flecainide (300 mg) as a single oral loading dose; or (2) amiodarone (5 mg/kg) as an intravenous bolus, followed by 1." | 9.07 | Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. ( Binetti, N; Boriani, G; Capucci, A; Cavazza, M; Fontana, G; Lenzi, T; Magnani, B; Trisolino, G, 1992) |
| "Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone." | 8.82 | [Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone]. ( Barta, K; Lorincz, I; Nagy, E; Simkó, J; Szabó, Z; Varga, E, 2004) |
| "Poisoning with flecainide acetate is rare and associated with a high mortality." | 8.80 | [Severe flecainide acetate poisoning. Apropos of a case]. ( Chevrolet, JC; Elamly, A; Maury, P; Metzger, J; Schoenenberger, I; Veragut, B; Vuille, C, 1999) |
| "The prevalence of arrhythmia in patients with hypertension has gradually attracted widespread attention." | 5.56 | Amiodarone inhibits arrhythmias in hypertensive rats by improving myocardial biomechanical properties. ( Han, D; He, Y; Li, X; Liu, Y; Nie, Y, 2020) |
| "Our study provides evidence confirming the protective role of amiodarone, b-blockers, atrial pacing and posterior pericardiotomy against POAF as well as highlights the risk of untreated hypertension." | 5.22 | Risk and protective factors for atrial fibrillation after cardiac surgery and valvular interventions: an umbrella review of meta-analyses. ( Aggeli, C; Alfredsson, J; Charitakis, E; Charitos, EI; Dragioti, E; Foukarakis, E; Karlsson, LO; Korela, D; Stratinaki, M; Tsartsalis, D; Tsioufis, C; Vanky, F; Walfridsson, H, 2022) |
| "To report our experience using single high dose oral amiodarone for the cardioversion of recent onset atrial fibrillation to sinus rhythm in patient presenting with symptoms within 48 h." | 5.16 | Single high oral dose amiodarone for cardioversion of recent onset atrial fibrillation. ( Nadarasa, K; Williams, MJ, 2012) |
| "Sixty-two patients with recent-onset (less than or equal to 1 week) atrial fibrillation (New York Heart Association functional class 1 and 2) were randomized in a single-blind study to 1 of the following treatment groups: (1) flecainide (300 mg) as a single oral loading dose; or (2) amiodarone (5 mg/kg) as an intravenous bolus, followed by 1." | 5.07 | Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. ( Binetti, N; Boriani, G; Capucci, A; Cavazza, M; Fontana, G; Lenzi, T; Magnani, B; Trisolino, G, 1992) |
| " Extended-release nifedipine and amlodipine are the two most commonly used oral CCAs in the management of pediatric hypertension." | 4.83 | A review of calcium channel antagonists in the treatment of pediatric hypertension. ( Sahney, S, 2006) |
| " Treatment with amiodarone may lead to changes in thyroid tests results and to development of hypothyroidism or thyrotoxicosis." | 4.82 | [Thyroid and cardiovascular disorders]. ( Gajek, J; Zyśko, D, 2004) |
| "Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone." | 4.82 | [Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone]. ( Barta, K; Lorincz, I; Nagy, E; Simkó, J; Szabó, Z; Varga, E, 2004) |
| "Poisoning with flecainide acetate is rare and associated with a high mortality." | 4.80 | [Severe flecainide acetate poisoning. Apropos of a case]. ( Chevrolet, JC; Elamly, A; Maury, P; Metzger, J; Schoenenberger, I; Veragut, B; Vuille, C, 1999) |
| " Thus, the aim of this work was to determine the Th1/Th17 (IL-6, IL-2, TNF, IL-17 and IFN-γ) and Th2 (IL-4 and IL-10) serum profile in Venezuelan Chagasic patients stratified according amiodarone treatment, hypertension and arrhythmias." | 3.85 | Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status. ( Fresno, M; Gironès, N; Marques, J; Mendoza, I; Mijares, A; Rodríguez-Angulo, H; Villegas, M, 2017) |
| " These cutaneous lesions had appeared less than 2 months after initiation of amiodarone for supra-ventricular arrhythmia." | 3.85 | [Amiodarone-induced immune complex cutaneous vasculitis]. ( Fardet, L; Lebrun-Vignes, B; Ndiaye, M; Ortonne, N, 2017) |
| "The results suggest by three alternative and complementary ways (analysis of anatomy and cardiac function, metabolism and histological structure) that dronedarone has the potential to reverse the LVH induced by arterial hypertension in the SHR model of compensated ventricular hypertrophy." | 3.85 | Dronedarone produces early regression of myocardial remodelling in structural heart disease. ( Delgado-Baeza, E; Delgado-Martos, MJ; Desco, M; Gomez de Diego, JJ; Muñoz-Valverde, D; Quintana-Villamandos, B; Soto-Montenegro, ML, 2017) |
| "We evaluated the hypothesis that a relationship exists between inflammation and the outcome of pharmaceutical cardioversion with amiodarone in recent onset atrial fibrillation." | 3.74 | Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. ( Dragomanovits, S; Kalogeropoulos, AS; Kremastinos, DT; Papathanasiou, S; Rigopoulos, AG; Rizos, I; Sakadakis, EA; Tsiodras, S, 2007) |
| "Amiodarone is an antiarrhythmic agent commonly used to treat cardiac arrhythmias." | 3.71 | Intravenous amiodarone modifies autonomic balance and increases baroreflex sensitivity in conscious rats. ( de Melo Alves, R; Dias da Silva Valdo, J; Fazan, R; Malliani, A; Montano, N; Porta, A; Ruscone, TG; Salgado, HC; Viana Públio, CC, 2002) |
| "No predisposing factor for early recurrence was found." | 2.79 | Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. ( Balsam, P; Kiliszek, M; Kochanowski, J; Koźluk, E; Lodziński, P; Opolski, G; Piątkowska, A; Piątkowski, R; Scisło, P, 2014) |
| "In 32 subjects, 10 with postischemic dilated cardiomyopathy, 12 with hypertensive cardiomyopathy, and 10 healthy, we assessed QT(c) and QT variability index (QTVI) after administration of fresh pink grapefruit juice, placebo, amiodarone, or sotalol." | 2.73 | Effects of pink grapefruit juice on QT variability in patients with dilated or hypertensive cardiomyopathy and in healthy subjects. ( Ghiselli, A; Magnanti, M; Magrì, D; Marigliano, V; Matera, S; Mitra, M; Paroli, M; Pasquazzi, E; Piccirillo, G; Schifano, E; Velitti, S, 2008) |
| " Thus, co-administration of antioxidants with amiodarone may lead to the more widespread application of amiodarone, which is currently the most potent available antiarrhythmic agent, but its clinical use is limited due the potentially severe toxic effect In hypertensive patients with normal ejection fraction, the most common precursor condition of heart failure with preserved ejection fraction, the potential primary causal role of oxidative stress and inflammation in the left ventricular systolic, diastolic and atrial dysfunction, which are important determinants of the transition of hypertensive heart disease to heart failure with preserved ejection fraction was verified." | 2.52 | [The role of oxidative stress in amiodaron toxicity, in left ventricular dysfunction of hypertensive patients and in heart failure with preserved ejection fraction]. ( Vereckei, A, 2015) |
| "Amiodarone is an effective antiarrhythmic agent for preventing and treating atrial and ventricular arrhythmias." | 2.44 | Fatal amiodarone-induced hepatotoxicity: a case report and literature review. ( Chan, AL; Hsieh, HJ; Hsieh, YA; Lin, SJ, 2008) |
| " Investigators have hoped that these drugs would be as effective as sotalol and amiodarone but have fewer adverse effects." | 2.40 | The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol. ( MacNeil, DJ, 1997) |
| "Amiodarone is an extremely potent drug which is effective for both supraventricular as well as ventricular arrhythmias." | 2.36 | New antiarrhythmic drugs. ( Hess, DS; Scheinman, MM, 1983) |
| "The prevalence of arrhythmia in patients with hypertension has gradually attracted widespread attention." | 1.56 | Amiodarone inhibits arrhythmias in hypertensive rats by improving myocardial biomechanical properties. ( Han, D; He, Y; Li, X; Liu, Y; Nie, Y, 2020) |
| "She presented generalized skin rash, arthralgia on upper and lower extremities, associated with difficulty to walk." | 1.39 | An unexpected side-effect of a commonly used drug. ( Adorno, E; Fernández González, F; Fernández González, R; Miranda, S; Nieves, J; Santiago Casiano, M, 2013) |
| "Amiodarone was the most widely used active compound (82%) and apparently the most effective." | 1.39 | [Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs]. ( Alegret, JM; Freire, F; Romero-Menor, C; Viñolas, X, 2013) |
| "The strongest factor associated with AF recurrence was hsCRP at 48 h > or =2." | 1.36 | Hypertension and paroxysmal atrial fibrillation: a novel predictive role of high sensitivity C-reactive protein in cardioversion and long-term recurrence. ( Dragomanovits, S; Faviou, E; Kalogeropoulos, AS; Kremastinos, DT; Rigopoulos, AG; Rizos, I; Sakadakis, EA; Tsiodras, S, 2010) |
| "In amiodarone-treated groups, the most frequent chromosomal aberration was chromatid breaks." | 1.35 | Genotoxic studies in hypertensive and normotensive rats treated with amiodarone. ( Almeida, MR; Antunes, LM; Campos, MG; da Silva, VJ; de Oliveira Lima, E; Dias, FL; Salman, AK, 2008) |
| "Amlodipine did not affect cardiac hypertrophy." | 1.32 | Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. ( Allen, TJ; Burrell, LM; Cao, Z; Cooper, ME; Davis, BJ; Lassila, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (11.32) | 18.7374 |
| 1990's | 6 (11.32) | 18.2507 |
| 2000's | 19 (35.85) | 29.6817 |
| 2010's | 20 (37.74) | 24.3611 |
| 2020's | 2 (3.77) | 2.80 |
| Authors | Studies |
|---|---|
| Charitakis, E | 1 |
| Tsartsalis, D | 1 |
| Korela, D | 1 |
| Stratinaki, M | 1 |
| Vanky, F | 1 |
| Charitos, EI | 1 |
| Alfredsson, J | 1 |
| Karlsson, LO | 1 |
| Foukarakis, E | 1 |
| Aggeli, C | 1 |
| Tsioufis, C | 1 |
| Walfridsson, H | 1 |
| Dragioti, E | 1 |
| Nie, Y | 1 |
| He, Y | 1 |
| Han, D | 1 |
| Liu, Y | 1 |
| Li, X | 1 |
| Rodríguez-Angulo, H | 1 |
| Marques, J | 1 |
| Mendoza, I | 1 |
| Villegas, M | 1 |
| Mijares, A | 1 |
| Gironès, N | 1 |
| Fresno, M | 1 |
| Ndiaye, M | 1 |
| Lebrun-Vignes, B | 1 |
| Ortonne, N | 1 |
| Fardet, L | 1 |
| Quintana-Villamandos, B | 1 |
| Gomez de Diego, JJ | 1 |
| Delgado-Martos, MJ | 1 |
| Muñoz-Valverde, D | 1 |
| Soto-Montenegro, ML | 1 |
| Desco, M | 1 |
| Delgado-Baeza, E | 1 |
| Rao, DA | 1 |
| Lakdawala, NK | 1 |
| Miller, AL | 1 |
| Loscalzo, J | 1 |
| Deftereos, S | 1 |
| Giannopoulos, G | 1 |
| Kossyvakis, C | 1 |
| Efremidis, M | 1 |
| Panagopoulou, V | 1 |
| Raisakis, K | 1 |
| Kaoukis, A | 1 |
| Karageorgiou, S | 1 |
| Bouras, G | 1 |
| Katsivas, A | 1 |
| Pyrgakis, V | 1 |
| Stefanadis, C | 1 |
| Lodziński, P | 1 |
| Kiliszek, M | 1 |
| Koźluk, E | 1 |
| Piątkowska, A | 1 |
| Balsam, P | 1 |
| Kochanowski, J | 1 |
| Scisło, P | 1 |
| Piątkowski, R | 1 |
| Opolski, G | 2 |
| Fernández González, F | 1 |
| Miranda, S | 1 |
| Santiago Casiano, M | 1 |
| Nieves, J | 1 |
| Adorno, E | 1 |
| Fernández González, R | 1 |
| Páez, JL | 1 |
| Doiny, D | 1 |
| Estrada, A | 1 |
| Figueroa, J | 1 |
| Filgueiras-Rama, D | 1 |
| Merino, JL | 1 |
| Guo, X | 1 |
| Zhang, Y | 1 |
| Xu, G | 1 |
| Zhou, X | 1 |
| Li, L | 1 |
| Tang, B | 1 |
| Kurniawan, TG | 1 |
| Setiawati, A | 1 |
| Makmun, LH | 1 |
| Vereckei, A | 1 |
| Nouri, SN | 1 |
| Block, BL | 1 |
| Bobbo, M | 1 |
| Pinamonti, B | 1 |
| Merlo, M | 1 |
| Stolfo, D | 1 |
| Iorio, A | 1 |
| Ramani, F | 1 |
| Barbati, G | 1 |
| Carriere, C | 1 |
| Massa, L | 1 |
| Poli, S | 1 |
| Scapol, S | 1 |
| Gigli, M | 1 |
| Di Lenarda, A | 1 |
| Sinagra, G | 1 |
| Almeida, MR | 1 |
| de Oliveira Lima, E | 1 |
| da Silva, VJ | 1 |
| Campos, MG | 1 |
| Antunes, LM | 1 |
| Salman, AK | 1 |
| Dias, FL | 1 |
| Stiefelhagen, P | 1 |
| Montero-Pérez, FJ | 1 |
| Rizos, I | 2 |
| Rigopoulos, AG | 2 |
| Kalogeropoulos, AS | 2 |
| Tsiodras, S | 2 |
| Dragomanovits, S | 2 |
| Sakadakis, EA | 2 |
| Faviou, E | 1 |
| Kremastinos, DT | 2 |
| Jurado Román, A | 1 |
| Rubio Alonso, B | 1 |
| Martín Asenjo, R | 1 |
| Salguero Bodes, R | 1 |
| López Gil, M | 1 |
| Arribas Ynsaurriaga, F | 1 |
| Sung, PS | 1 |
| Yoon, SK | 1 |
| Nadarasa, K | 1 |
| Williams, MJ | 1 |
| Viñolas, X | 1 |
| Freire, F | 1 |
| Romero-Menor, C | 1 |
| Alegret, JM | 1 |
| Kasprzak, JD | 1 |
| Stępińska, J | 1 |
| Wożakowska Kapłon, B | 1 |
| Drożdż, J | 1 |
| Grajek, S | 1 |
| Rynkiewicz, A | 1 |
| Tykarski, A | 1 |
| Filipiak, KJ | 1 |
| Lassila, M | 1 |
| Davis, BJ | 1 |
| Allen, TJ | 1 |
| Burrell, LM | 1 |
| Cooper, ME | 1 |
| Cao, Z | 1 |
| Kulasingam, SL | 1 |
| Akiyama, T | 1 |
| Mounsey, JP | 1 |
| Ledingham, R | 1 |
| Hallstrom, AP | 1 |
| Zyśko, D | 1 |
| Gajek, J | 1 |
| Simkó, J | 1 |
| Barta, K | 1 |
| Szabó, Z | 1 |
| Varga, E | 1 |
| Nagy, E | 1 |
| Lorincz, I | 1 |
| Stippel, DL | 1 |
| Taylan, C | 1 |
| Schröder, W | 1 |
| Beckurts, KT | 1 |
| Hölscher, AH | 1 |
| Sahney, S | 1 |
| Pappone, C | 1 |
| Augello, G | 1 |
| Sala, S | 1 |
| Gugliotta, F | 1 |
| Vicedomini, G | 1 |
| Gulletta, S | 1 |
| Paglino, G | 1 |
| Mazzone, P | 1 |
| Sora, N | 1 |
| Greiss, I | 1 |
| Santagostino, A | 1 |
| LiVolsi, L | 1 |
| Pappone, N | 1 |
| Radinovic, A | 1 |
| Manguso, F | 1 |
| Santinelli, V | 1 |
| Minhaj, MM | 1 |
| Zvara, DA | 1 |
| Nayyar, P | 1 |
| Maslow, A | 1 |
| Mironchik, EV | 1 |
| Dolgosheĭ, TS | 1 |
| Liskovich, TG | 1 |
| Madeshkina, GA | 1 |
| Kokhkovski, AB | 1 |
| Tyshchenko, AD | 1 |
| Papathanasiou, S | 1 |
| Turner, S | 1 |
| Mathews, L | 1 |
| Pandharipande, P | 1 |
| Thompson, R | 1 |
| Chan, AL | 1 |
| Hsieh, HJ | 1 |
| Hsieh, YA | 1 |
| Lin, SJ | 1 |
| Vora, A | 1 |
| Piccirillo, G | 1 |
| Magrì, D | 1 |
| Matera, S | 1 |
| Magnanti, M | 1 |
| Pasquazzi, E | 1 |
| Schifano, E | 1 |
| Velitti, S | 1 |
| Mitra, M | 1 |
| Marigliano, V | 1 |
| Paroli, M | 1 |
| Ghiselli, A | 1 |
| Scheinman, MM | 1 |
| Hess, DS | 1 |
| Romano, M | 1 |
| Garbarini, U | 1 |
| Cazzani, E | 1 |
| Lara, PF | 1 |
| Hueb, WA | 1 |
| Achilli, A | 1 |
| Giacci, M | 1 |
| Capezzuto, A | 1 |
| De Luca, F | 1 |
| Guerra, R | 1 |
| Serra, N | 1 |
| Tereshchenko, IV | 1 |
| Tsepelev, VV | 1 |
| Ivanova, ES | 1 |
| Matiouchine, GV | 1 |
| Shulman, VA | 1 |
| Balog, AI | 1 |
| Bezruk, AP | 1 |
| Golovenkin, SE | 1 |
| MacNeil, DJ | 1 |
| Maury, P | 1 |
| Vuille, C | 1 |
| Metzger, J | 1 |
| Veragut, B | 1 |
| Schoenenberger, I | 1 |
| Elamly, A | 1 |
| Chevrolet, JC | 1 |
| Susano, R | 1 |
| Caminal, L | 1 |
| Ramos, D | 1 |
| Díaz, B | 1 |
| Louis, R | 1 |
| Melon, P | 1 |
| Kassab, A | 1 |
| Soyeur, D | 1 |
| Dias Da Silva, VJ | 1 |
| Cavalcante Viana, PC | 1 |
| de Melo Alves, R | 2 |
| Salgado, HC | 2 |
| Montano, N | 2 |
| Fazan, R | 2 |
| Dias da Silva Valdo, J | 1 |
| Viana Públio, CC | 1 |
| Ruscone, TG | 1 |
| Porta, A | 1 |
| Malliani, A | 1 |
| Charlier, R | 1 |
| Bauthier, J | 1 |
| Richard, J | 1 |
| Modica, G | 1 |
| Ferrante, R | 1 |
| Capucci, A | 1 |
| Lenzi, T | 1 |
| Boriani, G | 1 |
| Trisolino, G | 1 |
| Binetti, N | 1 |
| Cavazza, M | 1 |
| Fontana, G | 1 |
| Magnani, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Using Time-dependent Intravenous Infusions of Amiodarone for Conversions to Sinus Rhythms in Patients With Paroxysmal Atrial Fibrillation[NCT03432663] | Phase 4 | 60 participants (Actual) | Interventional | 2008-08-01 | Completed | ||
| Dual Shock Versus Single Shock Synchronized External Direct Current Cardioversion for Atrial Fibrillation - A Double-blinded Randomized Trial[NCT03943693] | Phase 4 | 100 participants (Actual) | Interventional | 2019-04-01 | Terminated (stopped due to Poor enrollment) | ||
| A Controlled Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Treating Paroxysmal Atrial Fibrillation. The Ablation for Paroxysmal Atrial Fibrillation (APAF2) Trial[NCT00340314] | Phase 4 | 198 participants | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for amiodarone and Hypertension
| Article | Year |
|---|---|
Risk and protective factors for atrial fibrillation after cardiac surgery and valvular interventions: an umbrella review of meta-analyses.
Topics: Amiodarone; Atrial Fibrillation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertensio | 2022 |
[The role of oxidative stress in amiodaron toxicity, in left ventricular dysfunction of hypertensive patients and in heart failure with preserved ejection fraction].
Topics: Amiodarone; Anti-Arrhythmia Agents; Heart Failure; Humans; Hypertension; Oxidative Stress; Stroke Vo | 2015 |
[Thyroid and cardiovascular disorders].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiovascular Diseases; Coronary Artery B | 2004 |
[Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Heart Failure; Hum | 2004 |
A review of calcium channel antagonists in the treatment of pediatric hypertension.
Topics: Amiodarone; Calcium Channel Blockers; Child; Felodipine; Humans; Hypertension; Isradipine; Nicardipi | 2006 |
Fatal amiodarone-induced hepatotoxicity: a case report and literature review.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injur | 2008 |
Approach to management of atrial fibrillation in the Indian scenario.
Topics: Age Factors; Amiodarone; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Anticoagul | 2007 |
New antiarrhythmic drugs.
Topics: Amiodarone; Angina Pectoris; Anti-Arrhythmia Agents; Blood Circulation; Bradycardia; Diltiazem; Half | 1983 |
[Control of recurrent ventricular tachycardia in a case of mitral valve prolapse and arterial hypertension, using the combination of disopyramide and amiodarone].
Topics: Amiodarone; Benzofurans; Disopyramide; Drug Therapy, Combination; Female; Heart Ventricles; Humans; | 1982 |
The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol.
Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Female; Heart Conduction System; Heart Failur | 1997 |
[Severe flecainide acetate poisoning. Apropos of a case].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Biological Availability; Calcium Gluconate | 1999 |
7 trials available for amiodarone and Hypertension
| Article | Year |
|---|---|
Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Convert | 2013 |
Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Chi-Square Distri | 2014 |
Single high oral dose amiodarone for cardioversion of recent onset atrial fibrillation.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Counte | 2012 |
Lower observed versus expected (based on U.S. age and gender specific rates) survival in patients treated for near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiac Output; Case-Control Studies; Cohort Studies; Conf | 2004 |
A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; | 2006 |
Effects of pink grapefruit juice on QT variability in patients with dilated or hypertensive cardiomyopathy and in healthy subjects.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Beverages; Cardiomyopathy, Dilated; | 2008 |
Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Atrial Fibrillation; Electrocardiography, Ambulatory; | 1992 |
35 other studies available for amiodarone and Hypertension
| Article | Year |
|---|---|
Amiodarone inhibits arrhythmias in hypertensive rats by improving myocardial biomechanical properties.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biomechanical Phenomena; Calcium; | 2020 |
Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status.
Topics: Adult; Aged; Amiodarone; Analysis of Variance; Arrhythmias, Cardiac; Biomarkers; Chagas Disease; Cyt | 2017 |
[Amiodarone-induced immune complex cutaneous vasculitis].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Back; Diabetes Mellitus, Type 2; Humans; H | 2017 |
Dronedarone produces early regression of myocardial remodelling in structural heart disease.
Topics: Amiodarone; Animals; Atrial Fibrillation; Atrial Remodeling; Dronedarone; Heart Diseases; Humans; Hy | 2017 |
Clinical problem-solving. In the thick of it.
Topics: alpha-Galactosidase; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomegaly; Codon, N | 2013 |
An unexpected side-effect of a commonly used drug.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arthralgia; Biopsy; Drug Eruptions; Drug Substitution; Dys | 2013 |
Dronedarone: an option in the treatment of ventricular arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Dronedarone; Humans; Hypertension; | 2013 |
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; China; Comor | 2014 |
QT interval prolongation associated with amiodarone use in Cipto Mangunkusumo Hospital, Jakarta.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Hypernatremia; | 2014 |
Triple Oral Antithrombotic Therapy: A Teachable Moment.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Chest Pain; Coronary Artery Disease; Drug-Elu | 2016 |
Comparison of Patient Characteristics and Course of Hypertensive Hypokinetic Cardiomyopathy Versus Idiopathic Dilated Cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin- | 2017 |
Genotoxic studies in hypertensive and normotensive rats treated with amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Blood Pressure; Bone Marrow Cells; Chromosome Aberratio | 2008 |
[A hypertensive patient with atrial fibrillation has increasing dyspnea. Cardiac or pulmonary etiology?].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dyspnea; Electric Countershock; Femal | 2009 |
[The aqueous formulation of amiodarone i.v. is safer than the formulation available in Spain].
Topics: Amiodarone; Anti-Arrhythmia Agents; Chemistry, Pharmaceutical; Humans; Hypertension; Injections, Int | 2011 |
Hypertension and paroxysmal atrial fibrillation: a novel predictive role of high sensitivity C-reactive protein in cardioversion and long-term recurrence.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Biomarkers; C-Reactiv | 2010 |
Proarrhythmic potential of amiodarone: an underestimated risk?
Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathy, Dilated | 2012 |
Amiodarone hepatotoxicity.
Topics: Acute Disease; Aged; Amiodarone; Chemical and Drug Induced Liver Injury; Humans; Hypertension; Male; | 2012 |
[Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Comorbidity; Diabete | 2013 |
[Optimum heart rate - the current goal of cardiovascular therapy. Position statement of the Polish Cardiac Society Working Group on Cardiovascular Drug Therapy].
Topics: Adrenergic beta-Agonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzazepines; Di | 2012 |
Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
Topics: Alanine; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Ani | 2003 |
Supraventricular tachyarrhythmia as early indicator of a complicated course after esophagectomy.
Topics: Adrenergic Agonists; Adrenergic beta-Antagonists; Age Factors; Amiodarone; Anastomosis, Surgical; An | 2005 |
Case 1-2007 morbidly obese patient undergoing cardiac surgery.
Topics: Amiodarone; Anesthesia, General; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Catheterizatio | 2007 |
[Long QT syndrome induced by cordaron and quinidine].
Topics: Amiodarone; Anemia, Hemolytic; Anti-Arrhythmia Agents; Female; Humans; Hypertension; Long QT Syndrom | 2007 |
Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; C-Reactive Protein | 2007 |
Dolasetron-induced torsades de pointes.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Antiemetics; Cardiopulmonary Resusc | 2007 |
[Cardiac function in normal and hypertensive subjects before and after the intravenous use of amiodarone. Radioisotope study].
Topics: Amiodarone; Benzofurans; Chemical Phenomena; Chemistry; Female; Heart; Hemodynamics; Humans; Hyperte | 1982 |
[Digoxin-quinidine and digoxin-amiodarone interactions. Effects on blood levels of the cardioactive glycoside].
Topics: Adult; Aged; Amiodarone; Benzofurans; Coronary Disease; Digoxin; Drug Interactions; Female; Heart Di | 1981 |
[Subclinical hypothyroidism in patients with ischemic heart disease].
Topics: Achilles Tendon; Aged; Amiodarone; Angina, Unstable; Arrhythmias, Cardiac; Euthyroid Sick Syndromes; | 1993 |
Combined transesophageal left atrial pacing and antiarrhythmic therapy in the treatment of atrial flutter.
Topics: Ambulatory Care; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Fun | 1996 |
Amiodarone induced lupus.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Hypertension; Lupus E | 1999 |
[How I treat...persistent atrial fibrillation, by internal cardioversion, in a patient with exreme obesity].
Topics: Alcoholism; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Body Mass Index | 2001 |
Antihypertensive action of amiodarone in spontaneously hypertensive rats.
Topics: Amiodarone; Animals; Antihypertensive Agents; Blood Pressure; Bradycardia; Diastole; Heart Rate; Hyp | 2001 |
Intravenous amiodarone modifies autonomic balance and increases baroreflex sensitivity in conscious rats.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Baroreflex; Blood Pressure; Consc | 2002 |
A potentially antianginal benzo [b]thiophene with an amiodarone-like haemodynamic profile.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angina Pectoris; Animals; Benzofurans; Blood Pressure; Card | 1975 |
[Clinical and experimental results of treatment with amiodarone in coronary insufficiency].
Topics: Aged; Amiodarone; Angina Pectoris; Arrhythmias, Cardiac; Benzofurans; Coronary Disease; Dipyridamole | 1975 |